Danish drugmaker ALK has garnered European approval for its house dust mite pill designed to help alleviate related allergic rhinitis and allergic asthma.
The house dust mite (HDM) sublingual allergy immunotherapy (SLIT) has been cleared for use in adult patients who continue to suffer from allergic rhinitis despite symptom-relieving medication, or when allergic asthma is not well controlled by inhaled corticosteroids.
The decision means that, over the next six months, patients in Europe will get access to an effective, home-based therapy for the first time, says ALK.
House dust mites are the most common cause of allergy in the world, affecting 90 million people in Europe, North America and Japan, and more than 100 million in China. Nearly 50% of all house dust mite-allergic rhinitis patients suffer from concomitant asthma.
ALK’s HDM SLIT-tablet is also being developed for a number of other global markets and indications, with partner MSD (or Merck & Co in the USA, Canada) for North America, Torii for Japan, Abbott for Russia and bioCSL for Australia and New Zealand.